CSL LIMITED - Charts / Financials

0.09%

$212.89

Market Cap $103.0B

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

REFRESH

Day
Open	$212.00		Day High	$213.35		Day Low	$210.50
Daily Volume	1120057

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	$212.75	100		1	$212.99	15

Directors & Senior Management

Dr. Paul F. Mckenzie	Chief Executive Officer, Managing Director, Non-Independent Executive Director
Ms. Joy Linton	Chief Financial Officer
Ms. Mary Oates	Chief Operating Officer
Ms. Roanne Parry	Chief Human Resources Officer
Mr. Mark Hill	Executive Vice President, Chief Digital Information Officer
Mr. Greg Boss	Executive Vice President - Legal and CSL Group General Counsel
Mr. Ken Lim	Executive Vice President, Chief Strategy Officer
Dr. William Mezzanotte	Executive Vice President, Head - Research & Development and Chief Medical Officer
Mr. Andy Schmeltz	Executive Vice President - CSL Behring
Mr. Herve Gisserot	Senior Vice President, General Manager - CSL Vifor
Dr. Brian Anthony Mcnamee	Independent Non-Executive Chairman of the Board
Dr. Megan Elizabeth Clark	Independent Non-Executive Director
Prof. Andrew Cuthbertson	Independent Non-Executive Director
Dr. Brian Daniels	Independent Non-Executive Director
Ms. Carolyn Judith Hewson	Independent Non-executive Director

Data source: Refinitiv

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $212.89		Change 0.190(0.09%)		Mkt cap ! $103.0B

Open	High	Low	Value	Volume
$212.00	$213.35	$210.50	$242.7M	1.120M

Buyers (Bids)

No.	Vol.	Price($)
1	100	$212.75

Sellers (Offers)

Price($)	Vol.	No.
$212.99	15	1

View Market Depth

No.	Vol.	Price($)
1	100	212.750
2	150	212.700
3	23	212.650
2	97	212.600
1	100	212.500

Price($)	Vol.	No.
212.990	15	1
213.000	120	2
213.050	2251	2
213.160	100	1
213.180	1919	1

Last trade - 16.17pm 29/08/2025 (20 minute delay)

CSL (ASX) Chart

CSL LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories